To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
CEVEC to Launch CAP-T™ Cell System – a Human Transient Expression Technology
Read time: Less than a minute
CEVEC Pharmaceuticals GmbH introduces novel CAP-T™ transient expression system for serum-free and high yield protein production. CAP-T™ Technology is the logic result of today’s demand towards creating an efficient, integrated platform for transient production of complex biologics.
With CAP-T™ customers can proceed from gene to milligram and gram amounts of protein within only two weeks. Fast process times, high yields and authentic human post-translational modifications especially with complex and highly glycosylated proteins are key features and make it an ideal tool for screening, assay development, target validation, drug discovery, early stage pre-clinical drug development, and lead optimization.
Dr. Rainer Lichtenberger, CEO of CEVEC, comments: “Starting with transient protein expression using CAP-T™ and moving forward with stable expression using CAP® cells, CEVEC is now able to offer a continuum for rapid and versatile biopharmaceutical drug development from initial research ideas up to GMP-compliant manufacturing of clinical samples and market supplies.”
CAP-T™ cells are based on CAP® cells and match all their positive features with regard to comprehensive documentation, safety, non-tumor origin, and growth as suspension culture in serum- and protein-free media optimized for industrial use. CAP-T™ is available under flexible research license arrangements.
With CAP-T™ customers can proceed from gene to milligram and gram amounts of protein within only two weeks. Fast process times, high yields and authentic human post-translational modifications especially with complex and highly glycosylated proteins are key features and make it an ideal tool for screening, assay development, target validation, drug discovery, early stage pre-clinical drug development, and lead optimization.
Dr. Rainer Lichtenberger, CEO of CEVEC, comments: “Starting with transient protein expression using CAP-T™ and moving forward with stable expression using CAP® cells, CEVEC is now able to offer a continuum for rapid and versatile biopharmaceutical drug development from initial research ideas up to GMP-compliant manufacturing of clinical samples and market supplies.”
CAP-T™ cells are based on CAP® cells and match all their positive features with regard to comprehensive documentation, safety, non-tumor origin, and growth as suspension culture in serum- and protein-free media optimized for industrial use. CAP-T™ is available under flexible research license arrangements.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
